1. Academic Validation
  2. The effect of chronic atypical antipsychotic drugs and haloperidol on amphetamine-induced dopamine release in vivo

The effect of chronic atypical antipsychotic drugs and haloperidol on amphetamine-induced dopamine release in vivo

  • Brain Res. 1992 Mar 6;574(1-2):98-104. doi: 10.1016/0006-8993(92)90805-j.
J Ichikawa 1 H Y Meltzer
Affiliations

Affiliation

  • 1 Laboratory of Biological Psychiatry, Case Western Reserve University, Cleveland, OH 44106.
Abstract

The effect of chronic administration of antipsychotic drugs (21 days in drinking water followed by 3 days drug washout) on the D-amphetamine (1.0 mg/kg, s.c.)-induced increase in dopamine (DA) release in the striatum and the nucleus accumbens of awake, freely-moving rats was investigated with microdialysis. Chronic administration of haloperidol, a typical antipsychotic, (0.5 mg/kg/day), decreased basal extracellular DA release in the striatum and the nucleus accumbens but did not affect D-amphetamine-induced DA release in either region. In marked contrast, chronic administration of three atypical antipsychotic drugs: amperozide (2 mg/kg/day), clozapine (10 mg/kg/day) and melperone (2 mg/kg/day) increased basal extracellular DA and enhanced D-amphetamine-induced DA release in the striatum. In the nucleus accumbens, basal extracellular DA was decreased by chronic amperozide, unchanged by chronic clozapine and increased by chronic melperone. Most significantly, D-amphetamine-induced DA release was inhibited by chronic amperozide or clozapine, but unaffected by chronic melperone in this region. These results suggest that atypical antipsychotic drugs can alter DA release in a region specific manner. In particular, attenuation of amphetamine-like stimulation of DA release with reduced basal DA release in the nucleus accumbens could contribute to the antipsychotic action of amperozide which has a very weak affinity for D2 DA receptors.

Figures
Products